AHAnne-Sophie Hérard

Anne-Sophie Hérard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne-Sophie Hérard has a total of 232 co-authors. Here are the top co-authors by number of shared publications:

  • Philippe Hantraye

    Université Paris-Saclay, Commissariat à l’Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique, MIRCen, Laboratoire des Maladies Neurodégénératives, 92265, Fontenay-aux-Roses, France

    20 shared publications
  • Marc Dhenain

    Neuro-Bicêtre, Inserm U1195, CNRS EMR2000, Université Paris-Saclay, Bâtiment Gregory Pincus, Le Kremlin Bicêtre, France

    15 shared publications
  • Thierry Delzescaux

    Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Département de la Recherche Fondamentale, Institut François Jacob, Molecular Imaging Center (MIRCen), CNRS UMR 9199, Université Paris-Sud, Université Paris-Saclay, Fontenay-aux-Roses, France

    14 shared publications
  • Gilles Bonvento

    Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France

    11 shared publications
  • Martine Guillermier

    Paris-Saclay University, CNRS, Institut des Neurosciences Paris-Saclay, Saclay, France

    9 shared publications
  • Michel E. Vandenberghe

    CEA, DRF, Institut François Jacob Molecular Imaging Research Center, Fontenay-aux-Roses, France

    9 shared publications

Latest Publications

  • Open Access

    An AAV model of tauopathy targeting the mouse dentate gyrus reveals greater trans-synaptic tau spreading with aggregation-prone tau variants

    by Pauline Leal, Charlotte Duwat, Cecile Adamski, Marie-Claude Gaillard, Gwennaelle Auregan, Martine Guillermier, Sueva Bernier, Noelle Dufour, Fanny Petit, Caroline Jan, et al.

    Alzheimer's disease is characterized by progressive memory and cognitive decline, which is strongly correlated with the anatomical progression of tau pathology. Resulting from the intraneuronal aggregation of misfolded tau protein, tauopathy propagates in an anterograde manner between synaptically connected neurons through a prion-like mechanism. While glial cells, particularly microglia, are implicated in this process, the precise mechanisms underlying tauopathy propagation remain poorly understood. A critical unresolved question is whether aggregated or soluble pathologic tau forms mediate this spread. Here, we show in vivo that tau spreading scales with the aggregation propensity of the tau variant expressed. We developed a mouse model using adeno-associated virus (AAV)-mediated gene transfer to overexpress distinct tau forms in the dentate gyrus, alongside a reporter gene. This design enabled discrimination between transduced neurons and those secondarily affected by pathology propagation. Leveraging contralateral neuronal projections, we quantified propagation levels. To investigate the role of microglia and of extracellular vesicles, we analyzed microglial morphology in response to different tau forms and measured tau protein levels in extracellular vesicles isolated from injected mouse brains. We first confirmed the presence of vector-derived tau protein in non-transduced neurons, validating our model for studying tau propagation. We then found that aggregation-prone tau variants were associated with a greater number of tau-positive neurons in the contralateral hippocampus than wild-type tau. Additionally, extracellular vesicles from brains injected with aggregated tau contained higher levels of tau protein. Given that insoluble tau aggregates represent the ultimate stage of tauopathy, our findings suggest that propagation occurs at advanced stages of tau pathology, and that extracellular vesicles may contribute to the transfer of pathological tau, although the cellular origin of these vesicles was not determined in this study. Furthermore, our model provides a robust experimental paradigm for exploring therapeutic strategies aimed at inhibiting tauopathy propagation.

  • Open Access

    Reactive astrocytes promote proteostasis in Huntington’s disease through the JAK2-STAT3 pathway

    by Laurene Abjean, Lucile Ben Haim, Miriam Riquelme-Perez, Pauline Gipchtein, Céline Derbois, Marie-Ange Palomares, Fanny Petit, Anne-Sophie Hérard, Marie-Claude Gaillard, Martine Guillermier, et al.

    Huntington’s disease is a fatal neurodegenerative disease characterized by striatal neurodegeneration, aggregation of mutant Huntingtin and the presence of reactive astrocytes. Astrocytes are important partners for neurons and engage in a specific reactive response in Huntington’s disease that involves morphological, molecular and functional changes. How reactive astrocytes contribute to Huntington’s disease is still an open question, especially because their reactive state is poorly reproduced in experimental mouse models. Here, we show that the JAK2-STAT3 pathway, a central cascade controlling astrocyte reactive response, is activated in the putamen of Huntington’s disease patients. Selective activation of this cascade in astrocytes through viral gene transfer reduces the number and size of mutant Huntingtin aggregates in neurons and improves neuronal defects in two complementary mouse models of Huntington’s disease. It also reduces striatal atrophy and increases glutamate levels, two central clinical outcomes measured by non-invasive magnetic resonance imaging. Moreover, astrocyte-specific transcriptomic analysis shows that activation of the JAK2-STAT3 pathway in astrocytes coordinates a transcriptional program that increases their intrinsic proteolytic capacity, through the lysosomal and ubiquitin-proteasome degradation systems. This pathway also enhances their production and exosomal release of the co-chaperone DNAJB1, which contributes to mutant Huntingtin clearance in neurons. Together, our results show that the JAK2-STAT3 pathway controls a beneficial proteostasis response in reactive astrocytes in Huntington’s disease, which involves bi-directional signalling with neurons to reduce mutant Huntingtin aggregation, eventually improving disease outcomes.


  • Open Access

    Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice

    by Suzanne Lam, Anne-Sophie Hérard, Susana Boluda, Fanny Petit, Sabiha Eddarkaoui, Karine Cambon, The Brainbank Neuro-Ceb Neuropathology Network, Jean-Luc Picq, Luc Buée, Charles Duyckaerts, et al.

    Alzheimer’s disease (AD) is characterized by intracerebral accumulations of extracellular amyloid-β (Aβ) plaques and intracellular tau pathology that spread in the brain. Tau lesions occur in the form of neuropil threads, neurofibrillary tangles, and neuritic plaques i.e. tau aggregates within neurites surrounding Aβ deposits. The cascade of events linking these lesions and synaptic or memory impairments are still debated. Intracerebral infusion of human AD brain extracts in Aβ plaque-bearing mice that do not overexpress pathological tau proteins induces tau pathologies following heterotopic seeding of mouse tau protein. There is however little information regarding the downstream events including synaptic or cognitive repercussions of tau pathology induction in these models. In the current study, human AD brain extracts (AD be ) and control-brain extracts (Ctrl be ) were infused in the hippocampus of Aβ plaque-bearing APP swe /PS1 dE9 mice. Memory, synaptic density, as well as Aβ plaque and tau aggregate loads, microgliosis, astrogliosis at the inoculation site and in connected regions (perirhinal/entorhinal cortex) were evaluated 4 and 8 months post-inoculation. AD be inoculation induced memory deficit. It increased deposition of Aβ plaques close to the inoculation site. Tau pathology was also induced in AD be -inoculated mice. Neuropil threads and neurofibrillary tangles occurred next to the inoculation site and spread to connected regions notably the perirhinal/entorhinal cortex. Neuritic plaque pathology was detected in both AD be - and Ctrl be - inoculated animals but AD be inoculation increased the severity close and at distance of the inoculation site. Finally, AD be inoculation reduced synaptic density close to the inoculation site and in connected regions as the perirhinal/entorhinal cortex. Synaptic impairments were correlated with increased severity of neuritic plaques but not of other tau lesions or Aβ lesions, which suggests that neuritic plaques are a culprit for synaptic loss. Synaptic density was also associated with microglial load. Graphical


  • Open Access

    Heterogeneity of Alzheimer’s disease: Insight from a novel mouse model of amyloid and tau lesions based on the inoculation of human brain preparations

    by Suzanne Lam, Susana Boluda, Anne‐Sophie Herard, Fanny Petit, Charles Duyckaerts, Benoit Delatour, Stéphane Haïk, Marc Dhenain

    Background: A major challenge in clinical research is to better understand the heterogeneity of AD. Indeed, AD is heterogeneous regarding its origin, neuropathology and clinical expressions. While classical sporadic forms of AD (clAD) evolve over approximately 10 years, the “rapidly progressive form of AD” (rAD) is a non‐genetic aggressive form associated with a rapid clinical decline that evolves over approximately 2 years (Schmidt et al., Arch Neurol. 2011). Several studies have shown that the experimental inoculation of brain samples with Aβ‐ and/or tau pathology into transgenic (tg) mouse models overexpressing mutant human APP or tau promotes either Aβ or tau aggregation in the brain of the recipient animal (Gary et al., Acta Neuropathol Com. 2019). The phenotype of the inoculated brains is moreover reproduced in the recipient host (Watts et al., PNAS. 2014). The aim of this work was to study the impact of the inoculations of rAD versus clAD‐human brain preparations in tg mice mouse models of β‐amyloidosis to explore the mechanisms associated to AD heterogeneity.Method: Brain samples were characterized pathologically and biochemically. The rAD, clAD, and ctrl (non‐Alzheimer) samples were inoculated in the CA1 region of 2‐month‐old APP/PS1dE9 mice (n = 15‐20/group). At 8 months post‐inoculation, an object recognition task (V‐maze) was conducted to assess memory performance. Aβ deposits (4G8 antibody), tau inclusions (AT8 antibody) and synaptic density were then quantified by immunohistochemistry in the hippocampus.Result: Mice inoculated with either rAD or clAD brain preparations developed a similar increase of Aβ plaques and tau deposits as compared to ctrl‐inoculated mice. However, only the aggressive form of AD (rAD) led to significant cognitive alterations (Figure 1) and synaptic loss (Figure 2) after 8 months.Conclusion: APP/PS1dE9 mice inoculated with AD brain preparations are new models to study both amyloid and tau lesions occurrence. Our results suggest that, independently from the amyloid plaque load or the severity of tau intraneuronal pathology, synaptic health variability may contribute to the heterogeneity of AD‐like phenotype. Acknowledgment: We thank France‐Alzheimer and the NeuroCEB/CNR‐prion brain banks.


  • Assessment of simplified methods for quantification of [18F]-DPA-714 using 3D whole-brain TSPO immunohistochemistry in a non-human primate

    by Nadja Van Camp, Yaël Balbastre, Anne-Sophie Herard, Sonia Lavisse, Clovis Tauber, Catriona Wimberley, Martine Guillermier, Aurélie Berniard, Pauline Gipchtein, Caroline Jan, et al.

    The 18 kDa translocator protein (TSPO) is the main molecular target to image neuroinflammation by positron emission tomography (PET). However, TSPO-PET quantification is complex and none of the kinetic modelling approaches has been validated using a voxel-by-voxel comparison of TSPO-PET data with the actual TSPO levels of expression. Here, we present a single case study of binary classification of in vivo PET data to evaluate the statistical performance of different TSPO-PET quantification methods. To that end, we induced a localized and adjustable increase of TSPO levels in a non-human primate brain through a viral-vector strategy. We then performed a voxel-wise comparison of the different TSPO-PET quantification approaches providing parametric [F-18]-DPA-714 PET images, with co-registered in vitro three-dimensional TSPO immunohistochemistry (3D-IHC) data. A data matrix was extracted from each brain hemisphere, containing the TSPO-IHC and TSPO-PET data for each voxel position. Each voxel was then classified as false or true, positive or negative after comparison of the TSPO-PET measure to the reference 3D-IHC method. Finally, receiver operating characteristic curves (ROC) were calculated for each TSPO-PET quantification method. Our results show that standard uptake value ratios using cerebellum as a reference region (SUVCBL) has the most optimal ROC score amongst all non-invasive approaches.


  • Open Access

    Encephalopathy induced by Alzheimer brain inoculation in a non-human primate

    by French Neuropathology Network, Charlotte Gary, Suzanne Lam, Anne-Sophie Hérard, James E. Koch, Fanny Petit, Pauline Gipchtein, Stephen J. Sawiak, Raphaëlle Caillierez, Sabiha Eddarkaoui, et al.

    Alzheimer’s disease is characterized by cognitive alterations, cerebral atrophy and neuropathological lesions including neuronal loss, accumulation of misfolded and aggregated β-amyloid peptides (Aβ) and tau proteins. Iatrogenic induction of Aβ is suspected in patients exposed to pituitary-derived hormones, dural grafts, or surgical instruments, presumably contaminated with Aβ. Induction of Aβ and tau lesions has been demonstrated in transgenic mice after contamination with Alzheimer’s disease brain homogenates, with very limited functional consequences. Unlike rodents, primates naturally express Aβ or tau under normal conditions and attempts to transmit Alzheimer pathology to primates have been made for decades. However, none of earlier studies performed any detailed functional assessments. For the first time we demonstrate long term memory and learning impairments in a non-human primate (Microcebus murinus) following intracerebral injections with Alzheimer human brain extracts. Animals inoculated with Alzheimer brain homogenates displayed progressive cognitive impairments (clinical tests assessing cognitive and motor functions), modifications of neuronal activity (detected by electroencephalography), widespread and progressive cerebral atrophy (in vivo MRI assessing cerebral volume loss using automated voxel-based analysis), neuronal loss in the hippocampus and entorhinal cortex (post mortem stereology). They displayed parenchymal and vascular Aβ depositions and tau lesions for some of them, in regions close to the inoculation sites. Although these lesions were sparse, they were never detected in control animals. Tau-positive animals had the lowest performances in a memory task and displayed the greatest neuronal loss. Our study is timely and important as it is the first one to highlight neuronal and clinical dysfunction following inoculation of Alzheimer’s disease brain homogenates in a primate. Clinical signs in a chronic disease such as Alzheimer take a long time to be detectable. Documentation of clinical deterioration and/or dysfunction following intracerebral inoculations with Alzheimer human brain extracts could lead to important new insights about Alzheimer initiation processes.


  • Open Access

    Voxel-Based Statistical Analysis of 3D Immunostained Tissue Imaging

    by Michel E. Vandenberghe, Nicolas Souedet, Anne-Sophie Hérard, Anne-Marie Ayral, Florent Letronne, Yaël Balbastre, Elmahdi Sadouni, Philippe Hantraye, Marc Dhenain, Frédérique Frouin, et al.

    Recently developed techniques to visualize immunostained tissues in 3D and in large samples have expanded the scope of microscopic investigations at the level of the whole brain. Here, we propose to adapt voxel-based statistical analysis to 3D high-resolution images of the immunostained rodent brain. The proposed approach was first validated with a simulation dataset with known cluster locations. Then, it was applied to characterize the effect of ADAM30, a gene involved in the metabolism of the amyloid precursor protein, in a mouse model of Alzheimer's disease. This work introduces voxel-based analysis of 3D immunostained microscopic brain images and, therefore, opens the door to localized whole-brain exploratory investigation of pathological markers and cellular alterations.


  • Open Access

    Plasma Amyloid Is Associated with White Matter and Subcortical Alterations and Is Modulated by Age and Seasonal Rhythms in Mouse Lemur Primates

    by Charlotte Gary, Anne-Sophie Hérard, Zoé Hanss, Marc Dhenain

    Accumulation of amyloid-β (Aβ) peptides in the brain is a critical early event in the pathogenesis of Alzheimer's disease (AD), the most common age-related neurodegenerative disorder. There is increasing interest in measuring levels of plasma Aβ since this could help in diagnosis of brain pathology. However, the value of plasma Aβ in such a diagnosis is still controversial and factors modulating its levels are still poorly understood. The mouse lemur (Microcebus murinus) is a primate model of cerebral aging which can also present with amyloid plaques and whose Aβ is highly homologous to humans'. In an attempt to characterize this primate model and to evaluate the potential of plasma Aβ as a biomarker for brain alterations, we measured plasma Aβ40 concentration in 21 animals aged from 5 to 9.5 years. We observed an age-related increase in plasma Aβ40 levels. We then evaluated the relationships between plasma Aβ40 levels and cerebral atrophy in these mouse lemurs. Voxel-based analysis of cerebral MR images (adjusted for the age/sex/brain size of the animals), showed that low Aβ40 levels are associated with atrophy of several white matter and subcortical brain regions. These results suggest that low Aβ40 levels in middle-aged/old animals are associated with brain deterioration. One special feature of mouse lemurs is that their metabolic and physiological parameters follow seasonal changes strictly controlled by illumination. We evaluated seasonal-related variations of plasma Aβ40 levels and found a strong effect, with higher plasma Aβ40 concentrations in winter conditions compared to summer. This question of seasonal modulation of Aβ plasma levels should be addressed in clinical studies. We also focused on the amplitude of the difference between plasma Aβ40 levels during the two seasons and found that this amplitude increases with age. Possible mechanisms leading to these seasonal changes are discussed.


  • Open Access

    A validation dataset for Macaque brain MRI segmentation

    by Yaël Balbastre, Denis Rivière, Nicolas Souedet, Clara Fischer, Anne-Sophie Hérard, Susannah Williams, Michel E. Vandenberghe, Julien Flament, Romina Aron-Badin, Philippe Hantraye, et al.


  • Open Access

    Potentiating tangle formation reduces acute toxicity of soluble tau species in the rat

    by Marie D’orange, Gwénaelle Aurégan, Dimitri Cheramy, Mylène Gaudin-Guérif, Sarah Lieger, Martine Guillermier, Lev Stimmer, Charlène Joséphine, Anne-Sophie Hérard, Marie-Claude Gaillard, et al.

    Tauopathies are neurodegenerative diseases characterized by the aggregation of tau protein. These pathologies exhibit a wide variety of clinical and anatomo-pathological presentations, which may result from different pathological mechanisms. Although tau inclusions are a common feature in all these diseases, recent evidence instead implicates small oligomeric aggregates as drivers of tau-induced toxicity. Hence in vivo model systems displaying either soluble or fibrillary forms of wild-type or mutant tau are needed to better identify their respective pathological pathways. Here we used adeno-associated viruses to mediate gene transfer of human tau to the rat brain to develop models of pure tauopathies. Two different constructs were used, each giving rise to a specific phenotype developing in less than 3 months. First, hTAUWT overexpression led to a strong hyperphosphorylation of the protein, which was associated with neurotoxicity in the absence of any significant aggregation. In sharp contrast, its co-expression with the pro-aggregation peptide TauRD-ΔK280 in the hTAUProAggr group strongly promoted its aggregation into Gallyas-positive neurofibrillary tangles, while preserving neuronal survival. Our results support the hypothesis that soluble tau species are key players of tau-induced neurodegeneration.